Rising profit at WuXi Biologics underscores drug sector rebound
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects…
Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
BRIEF: WuXi XDC’s revenue, profit jump in 2024
WuXi XDC Cayman Inc. (2268.HK), a provider of contract services for drug companies, said on Wednesday its revenue and profit rose sharply last year on strong demand for services related…
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe…
Potential U.S. targeting casts shadow over WuXi AppTec family
Proposed U.S. legislation could ban federal agencies and federally funded institutions from buying devices and services from Chinese biotech companies Key Takeaways: WuXi AppTec, which could be banned from doing…
FAST NEWS: WuXi XDC’s profit surges on growth in ADC market
The latest: WuXi XDC Cayman Inc. (2268.HK) announced Thursday that it expects to report its net profit last year jumped more than 80% from 2022, while its adjusted net profit and…
Recent Articles
Fortune smiles again on WuXi AppTec with profit surge
2359.HK
603259.SHG
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK
2359.HK
2268.HK
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi group wrestles with uncertainty over pharma tariffs
2268.HK
-
Fortune smiles again on WuXi AppTec with profit surge
2359.HK 603259.SHG
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Joinn Labs undermined by AI as FDA phases out animal drug testing
6127.HK 603127.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK 600276.SHG
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
